| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Over the last 12 months, insiders at Kiora Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Kiora Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Kiora Pharmaceuticals, Inc. have bought $60,189 and sold $15.19M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,250 shares for transaction amount of $4,600 was made by Stengone Carmine N. (director) on 2024‑09‑11.
| 2024-09-11 | Stengone Carmine N. | director | 1,250 0.0442% | $3.68 | $4,600 | -9.22% | ||
| 2024-09-10 | Shapiro Aron | director | 3,000 0.1039% | $3.60 | $10,800 | -7.14% | ||
| 2024-08-19 | TYLE PRAVEEN | director | 5,000 0.165% | $3.96 | $19,800 | -18.56% | ||
| 2024-08-19 | Walters-Hoffert Lisa | director | 1,250 0.0402% | $3.86 | $4,825 | -18.56% | ||
| 2024-08-14 | Tosca Melissa | CFO | 2,000 0.0667% | $3.21 | $6,420 | +6.29% | ||
| 2024-06-14 | Daniels Eric Joseph | Chief Development Officer | 1,431 0.0556% | $5.29 | $7,570 | -35.63% | ||
| 2024-06-14 | Tosca Melissa | EVP Finance | 100 0.0039% | $5.25 | $525 | -35.63% | ||
| 2024-06-13 | Strem Brian M. | President and CEO | 3,000 0.1101% | $5.00 | $14,997 | -28.72% | ||
| 2024-06-13 | Parsons Erin | director | 5,260 0.1885% | $4.88 | $25,669 | -28.72% | ||
| 2021-11-18 | Strem Brian M. | President and CEO | 17,853 0.1764% | $1.41 | $25,173 | -68.88% | ||
| 2021-08-02 | Sale | ARMISTICE CAPITAL, LLC | 10 percent owner | 192,775 1.8717% | $2.40 | $463,046 | -69.80% | |
| 2021-07-30 | Sale | ARMISTICE CAPITAL, LLC | 10 percent owner | 68,188 0.7096% | $2.69 | $183,562 | -70.83% | |
| 2021-07-29 | Sale | ARMISTICE CAPITAL, LLC | 400,000 4.0311% | $3.00 | $1.2M | -74.57% | ||
| 2021-07-28 | Sale | ARMISTICE CAPITAL, LLC | 375,443 3.7408% | $3.28 | $1.23M | -76.79% | ||
| 2021-07-27 | Sale | ARMISTICE CAPITAL, LLC | 2.38M 31.3018% | $5.09 | $12.11M | -79.90% | ||
| 2021-01-06 | ARMISTICE CAPITAL, LLC | 1.53M 21.542% | $5.22 | $8M | -32.02% | |||
| 2020-02-10 | ARMISTICE CAPITAL, LLC | 12,000 0.2683% | $6.04 | $72,480 | -18.43% | |||
| 2020-02-06 | ARMISTICE CAPITAL, LLC | 11,000 0.2463% | $6.18 | $67,980 | -20.16% | |||
| 2019-12-06 | Sale | GOLDBERG MORTON | director | 1,961 0.0619% | $6.93 | $13,590 | -27.54% | |
| 2019-11-12 | Sale | GOLDBERG MORTON | director | 2,001 0.06% | $4.29 | $8,584 | +12.00% |
| IPSA (INNOVEN PARTENAIRES S.A.) | 10 percent owner | 1460479 39.7092% | $2.89M | 1 | 0 | |
| Ventech Capital II | 10 percent owner | 1431814 38.9298% | $2.83M | 1 | 6 | |
| FROM STEPHEN | President and CEO | 1032465 28.0719% | $2.04M | 4 | 3 | |
| ARMISTICE CAPITAL, LLC | 10 percent owner | 785000 21.3435% | $1.55M | 31 | 5 | |
| Wirostko Barbara | Chief Medical Officer | 405534 11.0261% | $802,957.32 | 0 | 3 | |
| Romano Sarah | Chief Financial Officer | 262113 7.1266% | $518,983.74 | 3 | 3 | |
| MANZO MICHAEL P. | VP of Engineering | 174796 4.7526% | $346,096.08 | 0 | 3 | |
| Mann Brenda | VP of Research & Development | 174424 4.7424% | $345,359.52 | 0 | 3 | |
| Garanzini Michael | Chief Commercial Officer | 171250 4.6561% | $339,075.00 | 1 | 0 | |
| Strem Brian M. | President and CEO | 14531 0.3951% | $28,771.38 | 2 | 0 | <0.0001% |
| Tosca Melissa | CFO | 13599 0.3697% | $26,926.02 | 2 | 0 | <0.0001% |
| Daniels Eric Joseph | Chief Development Officer | 11222 0.3051% | $22,219.56 | 1 | 0 | <0.0001% |
| CHANEY PAUL G | director | 8333 0.2266% | $16,499.34 | 1 | 0 | |
| Parsons Erin | director | 5260 0.143% | $10,414.80 | 1 | 0 | <0.0001% |
| TYLE PRAVEEN | director | 5014 0.1363% | $9,927.72 | 1 | 0 | <0.0001% |
| Shapiro Aron | director | 3000 0.0816% | $5,940.00 | 1 | 0 | <0.0001% |
| Walters-Hoffert Lisa | director | 1250 0.034% | $2,475.00 | 1 | 0 | <0.0001% |
| Stengone Carmine N. | director | 1250 0.034% | $2,475.00 | 1 | 0 | <0.0001% |
| GOLDBERG MORTON | director | 0 0% | $0 | 0 | 7 |
$13,664,154 | 40 | -70.35% | $6.22M | |
$1,029,337 | 36 | -28.38% | $7.83M | |
$29,635,355 | 27 | 9.05% | $5.68M | |
$63,749,694 | 24 | -12.24% | $8.06M | |
$1,039,491 | 21 | -11.76% | $6.84M | |
$37,200,153 | 21 | -47.67% | $8.25M | |
$742,412 | 14 | -50.36% | $5.93M | |
$405,510 | 11 | -46.23% | $6.41M | |
$188,726 | 11 | -28.87% | $8.17M | |
Kiora Pharmaceuticals, Inc. (KPRX) | $120,379 | 10 | -24.48% | $7.28M |
$11,777,042 | 10 | -11.94% | $9.33M | |
$241,042 | 9 | -11.02% | $8.81M | |
$211,895 | 8 | -39.70% | $7.03M | |
$159,974 | 7 | -18.60% | $6.45M | |
$149,996 | 5 | 16.26% | $8.74M | |
$1,184,658 | 4 | -22.17% | $7.38M | |
$1,057,000 | 3 | 5.27% | $6.54M | |
$28,395 | 3 | 3.48% | $7.97M | |
$31,190 | 2 | -14.18% | $6.9M |
| Increased Positions | 9 | +50% | 189,013 | +30.68% |
| Decreased Positions | 6 | -33.33% | 98,237 | -15.94% |
| New Positions | 4 | New | 91,459 | New |
| Sold Out Positions | 2 | Sold Out | 15,868 | Sold Out |
| Total Postitions | 21 | +16.67% | 706,945 | +14.73% |
| Adar1 Capital Management, Llc | $339.00 | 4.2% | 167,941 | +830 | +0.5% | 2025-09-30 |
| Nantahala Capital Management, Llc | $316.00 | 3.91% | 156,427 | -54,683 | -25.9% | 2025-09-30 |
| Stonepine Capital Management, Llc | $284.00 | 3.52% | 140,598 | -37,402 | -21.01% | 2025-09-30 |
| Citadel Advisors Llc | $90.00 | 1.11% | 44,573 | +44,573 | New | 2025-09-30 |
| Drw Securities, Llc | $74.00 | 0.92% | 36,865 | +36,865 | New | 2025-09-30 |
| Vanguard Group Inc | $42.00 | 0.52% | 20,915 | +20,915 | New | 2025-09-30 |
| Geode Capital Management, Llc | $38.00 | 0.47% | 18,853 | +280 | +1.51% | 2025-09-30 |
| Renaissance Technologies Llc | $25.00 | 0.31% | 12,400 | +12,400 | New | 2025-09-30 |
| Two Sigma Investments, Lp | $24.00 | 0.3% | 11,984 | +11,984 | New | 2025-09-30 |
| Citigroup Inc | $8.00 | 0.1% | 3,884 | +3,849 | +10,997.14% | 2025-09-30 |